Observational studyAesthetic plastic surgery2026
Hypersensitivity Reactions to Injectable Fillers and Their Impact on Cosmetic Procedure Results.
Observational study in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInjectable dermal fillers are widely used in aesthetic medicine; however, immunologically mediated hypersensitivity reactions may negatively influence clinical and aesthetic outcomes. Understanding their incidence, clinical presentation, and consequences is essential for improving patient safety and treatment effectiveness.
objectiveTo evaluate the incidence, clinical characteristics, and impact of hypersensitivity reactions on aesthetic outcomes after dermal filler injections.
methodsA prospective observational study included 92 patients aged 25-64 years who underwent cosmetic filler injections at an aesthetic clinic in Poland between November and December 2024. The fillers used included hyaluronic acid, calcium hydroxyapatite, and polycaprolactone-based preparations. Patients were monitored for 30 days with follow-up visits on days 3, 7, 14, and 30. Hypersensitivity reactions were classified according to the Gell-Coombs classification (types I and IV). Clinical manifestations, severity, and laboratory parameters (IgE, C-reactive protein, and procalcitonin) were evaluated in selected cases. Aesthetic outcomes were assessed using the Global Aesthetic Improvement Scale (GAIS) and a Visual Analogue Scale (VAS) of patient satisfaction.
resultsHypersensitivity reactions occurred in 21 patients (22.8%). Delayed type IV reactions predominated (13.0%) and manifested with infiltrates, erythema, and pain occurring 5-14 days after injection, whereas immediate type I reactions were recorded in 9.8% of patients within the first 72 h. The highest reaction rates were observed with calcium hydroxyapatite and polycaprolactone fillers. Severe reactions required systemic therapy and were associated with elevated IgE levels in most cases. Patient satisfaction was significantly lower in the reaction group (VAS 5.9 ± 1.8 vs. 8.4 ± 1.1; p < 0.01). All reported aesthetic complications, including fibrosis and hyperpigmentation, occurred exclusively in patients with hypersensitivity reactions.
conclusionHypersensitivity reactions to dermal fillers occur relatively frequently and significantly affect aesthetic outcomes and patient satisfaction. Individual risk assessment, careful filler selection, and extended post-procedure monitoring are necessary to minimise complications. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42298157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.